Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas

Sara Sheikhbahaei, Charles Marcus, Nima Hafezi-Nejad, Mehdi Taghipour, Rathan M. Subramaniam

Research output: Contribution to journalArticle

Abstract

Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.

Original languageEnglish (US)
Pages (from-to)375-393
Number of pages19
JournalPET Clinics
Volume10
Issue number3
DOIs
StatePublished - Jul 1 2015

Fingerprint

Sarcoma
tumors
tomography
cancer
Tomography
Neoplasm Grading
Neoplasm Staging
stratification
bones
therapy
Bone and Bones
Recurrence
Survival
predictions
Therapeutics

Keywords

  • Computed tomography
  • Fluorodeoxyglucose
  • Patient management
  • PET
  • Skeletal sarcoma
  • Soft tissue sarcoma

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Radiation

Cite this

Sheikhbahaei, S., Marcus, C., Hafezi-Nejad, N., Taghipour, M., & Subramaniam, R. M. (2015). Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. PET Clinics, 10(3), 375-393. https://doi.org/10.1016/j.cpet.2015.03.003

Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. / Sheikhbahaei, Sara; Marcus, Charles; Hafezi-Nejad, Nima; Taghipour, Mehdi; Subramaniam, Rathan M.

In: PET Clinics, Vol. 10, No. 3, 01.07.2015, p. 375-393.

Research output: Contribution to journalArticle

Sheikhbahaei, S, Marcus, C, Hafezi-Nejad, N, Taghipour, M & Subramaniam, RM 2015, 'Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas', PET Clinics, vol. 10, no. 3, pp. 375-393. https://doi.org/10.1016/j.cpet.2015.03.003
Sheikhbahaei S, Marcus C, Hafezi-Nejad N, Taghipour M, Subramaniam RM. Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. PET Clinics. 2015 Jul 1;10(3):375-393. https://doi.org/10.1016/j.cpet.2015.03.003
Sheikhbahaei, Sara ; Marcus, Charles ; Hafezi-Nejad, Nima ; Taghipour, Mehdi ; Subramaniam, Rathan M. / Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas. In: PET Clinics. 2015 ; Vol. 10, No. 3. pp. 375-393.
@article{6b0cfc2745f64b54988efa170bcbc1ad,
title = "Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas",
abstract = "Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.",
keywords = "Computed tomography, Fluorodeoxyglucose, Patient management, PET, Skeletal sarcoma, Soft tissue sarcoma",
author = "Sara Sheikhbahaei and Charles Marcus and Nima Hafezi-Nejad and Mehdi Taghipour and Subramaniam, {Rathan M.}",
year = "2015",
month = "7",
day = "1",
doi = "10.1016/j.cpet.2015.03.003",
language = "English (US)",
volume = "10",
pages = "375--393",
journal = "PET Clinics",
issn = "1556-8598",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Value of FDG PET/CT in patient management and outcome of skeletal and soft tissue sarcomas

AU - Sheikhbahaei, Sara

AU - Marcus, Charles

AU - Hafezi-Nejad, Nima

AU - Taghipour, Mehdi

AU - Subramaniam, Rathan M.

PY - 2015/7/1

Y1 - 2015/7/1

N2 - Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.

AB - Fluorodeoxyglucose (FDG)-PET/computed tomography (CT) has been increasingly used in bone and soft tissue sarcomas and provides advantages in the initial tumor staging, tumor grading, therapy assessment, and recurrence detection. FDG-PET/CT metabolic parameters are reliable predictors of survival in sarcomas and could be implemented in risk stratification models along with other prognostic factors in these patients.

KW - Computed tomography

KW - Fluorodeoxyglucose

KW - Patient management

KW - PET

KW - Skeletal sarcoma

KW - Soft tissue sarcoma

UR - http://www.scopus.com/inward/record.url?scp=84931955662&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84931955662&partnerID=8YFLogxK

U2 - 10.1016/j.cpet.2015.03.003

DO - 10.1016/j.cpet.2015.03.003

M3 - Article

VL - 10

SP - 375

EP - 393

JO - PET Clinics

JF - PET Clinics

SN - 1556-8598

IS - 3

ER -